(EMR) Emerson Electric - Overview
Stock: Valves, Analyzers, Automation, Software, Tools
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.71% |
| Yield on Cost 5y | 2.82% |
| Yield CAGR 5y | 1.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | 46.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.1% |
| Relative Tail Risk | -7.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 0.21 |
| Character TTM | |
|---|---|
| Beta | 1.246 |
| Beta Downside | 1.357 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.62% |
| CAGR/Max DD | 0.72 |
Description: EMR Emerson Electric January 27, 2026
Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm that serves process, industrial, and consumer markets worldwide through six operating segments: Final Control (valves, actuators, regulators), Measurement & Analytical (pressure, temperature, flow and gas sensors), Discrete Automation (solenoid/pneumatic valves, motion solutions, automation software), Safety & Productivity (hand and power tools for professionals and DIY users), Control Systems & Software (DeltaV and Ovation platforms that integrate plant data), and Test & Measurement (automated test equipment). The company, founded in 1890 and based in St. Louis, Missouri, markets its products under brands such as Anderson-Greenwood, Rosemount, ASCO, Greenlee, and RIDGID.
In its most recent fiscal year (FY 2025), Emerson reported revenue of roughly $19.1 billion, a 4.2 % increase YoY, driven primarily by a 7 % rise in Final Control sales and a 5 % boost in Measurement & Analytical shipments. Operating margin expanded to 13.5 % as cost-saving initiatives offset modest softening in oil-and-gas capex, which fell about 5 % year-over-year. A key sector driver remains the accelerating demand for automation in renewable-energy projects, where capital spending is up ~12 % and is expected to lift discrete-automation and control-systems sales over the next 12-24 months. The Safety & Productivity segment continues to benefit from a robust DIY market, with U.S. home-improvement spending projected to grow 3-4 % annually through 2027.
For a deeper dive into Emerson’s valuation metrics, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 2.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.23 > 1.0 |
| NWC/Revenue: -6.74% < 20% (prev 25.44%; Δ -32.18% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.10b > Net Income 2.29b |
| Net Debt (12.21b) to EBITDA (4.95b): 2.47 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (565.5m) vs 12m ago -1.55% < -2% |
| Gross Margin: 52.84% > 18% (prev 0.51%; Δ 5233 % > 0.5%) |
| Asset Turnover: 41.79% > 50% (prev 39.53%; Δ 2.26% > 0%) |
| Interest Coverage Ratio: 9.15 > 6 (EBITDA TTM 4.95b / Interest Expense TTM 356.0m) |
Altman Z'' 5.42
| A: -0.03 (Total Current Assets 8.58b - Total Current Liabilities 9.80b) / Total Assets 41.96b |
| B: 0.97 (Retained Earnings 40.60b / Total Assets 41.96b) |
| C: 0.08 (EBIT TTM 3.26b / Avg Total Assets 43.10b) |
| D: 1.86 (Book Value of Equity 40.26b / Total Liabilities 21.67b) |
| Altman-Z'' Score: 5.42 = AAA |
Beneish M -3.02
| DSRI: 1.03 (Receivables 3.10b/2.93b, Revenue 18.02b/17.49b) |
| GMI: 0.96 (GM 52.84% / 50.79%) |
| AQI: 1.03 (AQ_t 0.71 / AQ_t-1 0.69) |
| SGI: 1.03 (Revenue 18.02b / 17.49b) |
| TATA: -0.02 (NI 2.29b - CFO 3.10b) / TA 41.96b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of EMR shares?
Over the past week, the price has changed by +3.00%, over one month by +6.48%, over three months by +9.09% and over the past year by +20.99%.
Is EMR a buy, sell or hold?
- StrongBuy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the EMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 156 | 2.5% |
| Analysts Target Price | 156 | 2.5% |
| ValueRay Target Price | 174.1 | 14.5% |
EMR Fundamental Data Overview February 03, 2026
P/E Forward = 20.3252
P/S = 4.5868
P/B = 3.7685
P/EG = 1.4016
Revenue TTM = 18.02b USD
EBIT TTM = 3.26b USD
EBITDA TTM = 4.95b USD
Long Term Debt = 8.32b USD (from longTermDebt, last quarter)
Short Term Debt = 4.93b USD (from shortTermDebt, last quarter)
Debt = 13.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 94.85b USD (82.64b + Debt 13.76b - CCE 1.54b)
Interest Coverage Ratio = 9.15 (Ebit TTM 3.26b / Interest Expense TTM 356.0m)
EV/FCF = 35.56x (Enterprise Value 94.85b / FCF TTM 2.67b)
FCF Yield = 2.81% (FCF TTM 2.67b / Enterprise Value 94.85b)
FCF Margin = 14.80% (FCF TTM 2.67b / Revenue TTM 18.02b)
Net Margin = 12.73% (Net Income TTM 2.29b / Revenue TTM 18.02b)
Gross Margin = 52.84% ((Revenue TTM 18.02b - Cost of Revenue TTM 8.50b) / Revenue TTM)
Gross Margin QoQ = 51.91% (prev 52.56%)
Tobins Q-Ratio = 2.26 (Enterprise Value 94.85b / Total Assets 41.96b)
Interest Expense / Debt = 0.67% (Interest Expense 92.0m / Debt 13.76b)
Taxrate = 20.10% (160.0m / 796.0m)
NOPAT = 2.60b (EBIT 3.26b * (1 - 20.10%))
Current Ratio = 0.88 (Total Current Assets 8.58b / Total Current Liabilities 9.80b)
Debt / Equity = 0.68 (Debt 13.76b / totalStockholderEquity, last quarter 20.28b)
Debt / EBITDA = 2.47 (Net Debt 12.21b / EBITDA 4.95b)
Debt / FCF = 4.58 (Net Debt 12.21b / FCF TTM 2.67b)
Total Stockholder Equity = 19.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.32% (Net Income 2.29b / Total Assets 41.96b)
RoE = 11.48% (Net Income TTM 2.29b / Total Stockholder Equity 19.97b)
RoCE = 11.52% (EBIT 3.26b / Capital Employed (Equity 19.97b + L.T.Debt 8.32b))
RoIC = 8.07% (NOPAT 2.60b / Invested Capital 32.27b)
WACC = 9.09% (E(82.64b)/V(96.39b) * Re(10.51%) + D(13.76b)/V(96.39b) * Rd(0.67%) * (1-Tc(0.20)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.68%
[DCF Debug] Terminal Value 72.58% ; FCFF base≈2.77b ; Y1≈2.52b ; Y5≈2.22b
Fair Price DCF = 36.72 (EV 32.86b - Net Debt 12.21b = Equity 20.65b / Shares 562.3m; r=9.09% [WACC]; 5y FCF grow -11.07% → 2.90% )
EPS Correlation: 55.71 | EPS CAGR: 12.26% | SUE: 0.0 | # QB: 0
Revenue Correlation: 68.29 | Revenue CAGR: 12.17% | SUE: -0.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=20
EPS current Year (2026-09-30): EPS=6.48 | Chg30d=+0.013 | Revisions Net=+4 | Growth EPS=+8.0% | Growth Revenue=+5.1%
EPS next Year (2027-09-30): EPS=7.12 | Chg30d=+0.027 | Revisions Net=+3 | Growth EPS=+9.8% | Growth Revenue=+5.3%